stockrowLatest quarter
Spyre Therapeutics reported revenue of $0.00 for Q4 FY2023. The clinical-stage biotechnology company is developing antibody medicines for inflammatory bowel disease and rheumatic diseases, and it has not generated revenue from commercial product sales. Its investigational portfolio includes SPY001, SPY002 and SPY003 for inflammatory bowel disease, which it is studying both individually and in pairs.
For the later quarter to June 30, 2026, Spyre reported an adjusted loss per share of −$0.36, smaller than the consensus estimate of −$0.71. Diluted earnings per share for Q2 FY2026 were −$0.36, compared with −$0.49 for Q2 FY2025. Free cash flow was −$69.9 million for Q2 FY2026, compared with −$46.6 million for Q2 FY2025.
| Q4 FY2023 | A year before | Change | |
|---|---|---|---|
| Revenue | $0.00 | — | — |
| Diluted EPS | −$0.36 | −$0.49 | — |
| Free cash flow | −$69.9 million | −$46.6 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$0.36 | −$0.71 | Beat by 49.3% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
An earnings call for Spyre’s latest quarter is not available. The company is studying its inflammatory bowel disease antibodies individually and in pairs, and its rheumatic disease candidate separately.
Guidance
Management guidance for Spyre is not available. The company expects to need additional financing for research and development before a commercial drug can be produced, marketed and sold, and expects operating losses to increase as it continues clinical development and prepares for potential commercialization.